These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Protease inhibitors at Retroviruses Conference: Agouron's results.
    Author: James JS.
    Journal: AIDS Treat News; 1996 Mar 01; (no 242):5-6. PubMed ID: 11363194.
    Abstract:
    Agouron's protease inhibitor nelfinavir, still in its early development stage, reduces HIV viral load by about 98 percent after 4 weeks, and increases patients' CD4 counts. Agouron also reports that nelfinavir plus d4T has greater than 99 percent average reduction in viral load. The use of d4T alone is less effective. Nelfinavir is reported to have an excellent safety profile. Large trials are now recruiting at more than 40 sites in more than 30 U.S. cities. More information can be obtained by calling Agouron.
    [Abstract] [Full Text] [Related] [New Search]